Aims: Etoricoxib is a second-generation selective COX-2 inhibitor. There are a few researches investigating analgesic effect of Etoricoxib in dentistry.
Methods: This randomized, double-blind, active-control study included sixty patients with clinical pulpal diagnosis of necrosis of the first mandibular molar and an associated periapical radiolucency who experienced severe pain (more than 60 out of 100 in scale of Visual Analog Scale (VAS). The patients were equally randomized into four groups, who received 60 mg etoricoxib (group 1), 90 mg etoricoxib (group 2), 120 mg etoricoxib (group 3), and 400 mg ibuprofen (group 4). All patients randomly received a single dose of the drug after the first session of the root canal therapy. Using VAS, the severity of pain was recorded 2, 4, 6, 12, 24, 48, and 72 hours after the drug was administered.
Results: Changing trends of pain over the time was significant for all groups (P=0.003). In addition, there was not a significant difference between various study arms (P=0.146).
Conclusion: The results showed that ibuprofen had a comparable effect with various dosage of etoricoxib and may remain as the choice analgesic for dental pulpal pain.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Etoricoxib-NLC Mitigates Radiation-Induced Ovarian Damage in Rats: Insights into Pro-Inflammatory Cytokines, Antioxidant Activity, and Hormonal Responses.
Biomolecules
December 2024
Department of Biochemistry, Faculty of Science, University of Tabuk, Tabuk 71491, Saudi Arabia.
Radiotherapy is a critical treatment for cancer but poses significant risks to ovarian tissue, particularly in young females, leading to premature ovarian failure (POF). This study examines the therapeutic potential of etoricoxib nanostructured lipid carriers (ETO-NLC) in mitigating radiation-induced ovarian damage in female rats. Twenty-four female rats were randomly assigned to four groups: a control group receiving normal saline, a group exposed to a single dose of whole-body gamma radiation (6 Gy), a group treated with etoricoxib (10 mg/kg) post-radiation, and a group treated with ETO-NLC for 14 days following radiation.
View Article and Find Full Text PDFPotential Effect of Etoricoxib in Reducing Inflammation in Methotrexate-Induced Pulmonary Injury in Rats: Role of Oxidative Stress and the TLR4/p38-MAPK/NF-κB Signaling Pathway.
Inflammation
November 2024
Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt.
Article Synopsis
- Chemotherapy drugs like Methotrexate (MTX) can cause serious lung damage, with MTX being particularly toxic and having various side effects, including lung injury.
- The study investigated the effect of etoricoxib (ETO) in reducing MTX-induced lung damage in male rats, with different treatment groups comparing controls, MTX alone, ETO alone, and ETO after MTX.
- Results showed that ETO improved lung tissue structure and restored balance in oxidant/antioxidant levels, while also normalizing inflammatory markers and pathways linked to lung inflammation, suggesting ETO may protect against MTX toxicity.
Nephro- and Cardiotoxic Effects of Etoricoxib: Insights into Arachidonic Acid Metabolism and Beta-Adrenergic Receptor Expression in Experimental Mice.
Pharmaceuticals (Basel)
October 2024
Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Etoricoxib is a widely used anti-inflammatory drug, but its safety profile concerning cardiovascular and renal health remains inadequately explored. This study aimed to assess the nephro- and cardiotoxic effects of etoricoxib in a murine model, with a focus on its impact on arachidonic acid-metabolizing enzymes and beta-adrenergic receptors associated with drug-induced toxicity. Thirty-five mice were randomly assigned to five groups: control, low-dose etoricoxib, high-dose etoricoxib, low-dose celecoxib, and high-dose celecoxib (a well-known nephro- and cardiotoxic NSAID).
View Article and Find Full Text PDFMultimodal Analgesia Approach in Acute Low Back Pain Management: A Phase III Study of a Novel Analgesic Combination of Etoricoxib/Tramadol.
Pain Ther
December 2024
Laboratorios Silanes S.A. de C.V., Av. Paseo de las Palmas No. 340, 3rd floor, Lomas de Chapultepec, Miguel Hidalgo, 11000, Mexico City, Mexico.
Introduction: Pain and disability management are crucial for a speedy recovery. Combining analgesics with different mechanisms of action provides greater pain relief with lower doses, promoting efficient multimodal analgesia. This study evaluated the efficacy and safety between two fixed-dose combinations (FDC): etoricoxib/tramadol compared to paracetamol/tramadol for the management of acute low back pain (LBP) in a 7-day treatment.
View Article and Find Full Text PDFPrepacked Take-Home Analgesia in Outpatient Hand Surgery Reduces Opioid Dispensation.
Acta Chir Orthop Traumatol Cech
July 2024
Department of Orthopedics and Hand Surgery, University Hospital Örebro, Örebro, Sweden.
Background: Adequate postoperative pain treatment is important for quality of life, patient satisfaction, rehabilitation, function, and total opioid consumption, and might lower both the risk of chronic postoperative pain and the costs for society. Prolonged opioid consumption is a well-known risk factor for addiction. Previous studies in upper extremity surgery have shown that total opioid consumption is a third of the amount prescribed, which can be explained by package size.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!